Subtype
Endocrine Carcinoma
CI-CAN-00000838Explore in graph →
574 active trials16 approved drugs58 evidence items
- NCIt
- C215715
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000838Explore in graph →
Clinical trials
1,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (236)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03147404 | Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes(MS100070-0177) | completed | Phase 2 | 14 | Samsung Medical CenterOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT02248012 | Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) | completed | Phase 2 | 38 | Haukeland University HospitalOTHER |
| 1 |
| Dec 19, 2019 |
| clinicaltrials |
| NCT00388960 | Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 99 | CelgeneINDUSTRY | 5 | Nov 19, 2019 | clinicaltrials |
| NCT00654238 | Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer | completed | Phase 2 | 59 | University of PennsylvaniaOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT00617409 | To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid | completed | Phase 2 | 69 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00375193 | Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy | completed | Phase 2 | 75 | CelgeneINDUSTRY | 3 | Oct 24, 2019 | clinicaltrials |
| NCT00483509 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma(NGR007) | completed | Phase 2 | 28 | AGC Biologics S.p.A.INDUSTRY | 1 | Oct 4, 2019 | clinicaltrials |
| NCT01025284 | A Study for Participants With Small-Cell Lung Cancer | completed | Phase 2 | 64 | Eli Lilly and CompanyINDUSTRY | 3 | Sep 17, 2019 | clinicaltrials |
| NCT02250885 | KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | completed | Phase 2 | 14 | Gabrail Cancer Center ResearchOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT01266447 | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01833832 | Surgery and Heated Chemotherapy for Adrenocortical Carcinoma | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00416455 | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | completed | Phase 1 / Phase 2 | 384 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT01439568 | A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT02586350 | Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) | completed | Phase 2 / Phase 3 | 91 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 21, 2019 | clinicaltrials |
| NCT03059797 | Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) | completed | Phase 2 | 120 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 16, 2019 | clinicaltrials |
| NCT01253369 | Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT01173523 | Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 25 | David M. Jackman, MDOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02457273 | Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients | completed | Phase 2 | 23 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT00453895 | Sunitinib in Refractory Adrenocortical Carcinoma(SIRAC) | completed | Phase 2 | 39 | University of WuerzburgOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT03239171 | Bioinformation Therapy for Lung Cancer | completed | Phase 2 / Phase 3 | 120 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT01262235 | A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients | completed | Phase 1 / Phase 2 | 68 | Arbutus Biopharma CorporationINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT00309959 | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01497873 | A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer | completed | Phase 2 | 164 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Dec 27, 2018 | clinicaltrials |
| NCT02038647 | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 178 | Millennium Pharmaceuticals, Inc.INDUSTRY | 10 | Dec 27, 2018 | clinicaltrials |
| NCT00104871 | Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT00085293 | Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT02200081 | Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC(IMPULSE) | completed | Phase 2 | 103 | Mologen AGINDUSTRY | 4 | Nov 15, 2018 | clinicaltrials |
| NCT01901653 | Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 82 | StemcentrxINDUSTRY | 1 | Aug 9, 2018 | clinicaltrials |
| NCT00298896 | Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer | completed | Phase 2 | 55 | Sunesis PharmaceuticalsINDUSTRY | 2 | Jul 26, 2018 | clinicaltrials |
| NCT00098956 | 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2018 | clinicaltrials |
| NCT00527735 | Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 334 | Bristol-Myers SquibbINDUSTRY | 8 | Jul 18, 2018 | clinicaltrials |
| NCT01553916 | Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain | completed | Phase 1 / Phase 2 | 19 | Washington University School of MedicineOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01502410 | Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 3 | Jun 26, 2018 | clinicaltrials |
| NCT00445198 | A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies | completed | Phase 1 / Phase 2 | 86 | AbbVie (prior sponsor, Abbott)INDUSTRY | 3 | Jun 6, 2018 | clinicaltrials |
| NCT01811212 | Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2018 | clinicaltrials |
| NCT02806648 | A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)(PALBONET) | completed | Phase 2 | 21 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00528645 | AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Dec 7, 2017 | clinicaltrials |
| NCT00374140 | Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer | completed | Phase 2 | 40 | Ahmad TarhiniOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT02351128 | Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues(PHRC-Merkel) | completed | Phase 2 | 35 | University Hospital, GrenobleOTHER | 1 | Oct 18, 2017 | clinicaltrials |
| NCT01987232 | Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer | completed | Phase 1 / Phase 2 | 32 | AmgenINDUSTRY | 3 | Aug 28, 2017 | clinicaltrials |
| NCT01441297 | BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer | completed | Phase 2 | 24 | Ji-youn HanOTHER_GOV | 1 | Aug 25, 2017 | clinicaltrials |
| NCT00828139 | S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 189 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00856830 | Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | University of Alabama at BirminghamOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT00043862 | The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)((SCLC)) | completed | Phase 2 | 60 | GlaxoSmithKlineINDUSTRY | 1 | May 31, 2017 | clinicaltrials |
| NCT01166191 | Concurrent Chemo-radiotherapy With Intensity-Modulated Radiation Therapy (IMRT) for Limited Disease Small Cell Lung Cancer (LD-SCLC) | completed | Phase 2 | 60 | Maastricht Radiation OncologyOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT00519896 | Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT01514526 | Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma | completed | Phase 2 | 17 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT00729157 | Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Dec 30, 2019source: clinicaltrials